Zhejiang Orient Gene Biotech Co., Ltd. (688298.SS)
CNY 29.1
(-2.68%)
CNY 29.1
(-2.68%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 164.57 Million CNY | -95.94% |
| 2022 | 4.45 Billion CNY | -40.65% |
| 2021 | 7.5 Billion CNY | 189.99% |
| 2020 | 2.58 Billion CNY | 1382.66% |
| 2019 | 174.52 Million CNY | 25.43% |
| 2018 | 139.14 Million CNY | 28.95% |
| 2017 | 107.9 Million CNY | 23.13% |
| 2016 | 87.63 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 58 Million CNY | 9.83% |
| 2024 Q3 | 79.2 Million CNY | 85.38% |
| 2024 Q2 | 42.72 Million CNY | -26.34% |
| 2023 Q2 | 54.79 Million CNY | -55.48% |
| 2023 FY | 180.82 Million CNY | -95.94% |
| 2023 Q1 | 123.08 Million CNY | 38.98% |
| 2023 Q3 | 64.3 Million CNY | 17.36% |
| 2023 Q4 | 52.81 Million CNY | -17.87% |
| 2022 Q2 | 1.06 Billion CNY | -64.63% |
| 2022 FY | 4.45 Billion CNY | -40.65% |
| 2022 Q4 | 88.56 Million CNY | -68.39% |
| 2022 Q3 | 280.18 Million CNY | -73.75% |
| 2022 Q1 | 3.01 Billion CNY | 67.24% |
| 2021 Q1 | 1.68 Billion CNY | 0.62% |
| 2021 Q3 | 686 Million CNY | -79.4% |
| 2021 FY | 7.5 Billion CNY | 189.99% |
| 2021 Q4 | 1.8 Billion CNY | 163.01% |
| 2021 Q2 | 3.32 Billion CNY | 97.72% |
| 2020 Q3 | 228.44 Million CNY | -62.9% |
| 2020 Q1 | 69.79 Million CNY | 36.16% |
| 2020 FY | 2.58 Billion CNY | 1382.66% |
| 2020 Q4 | 1.67 Billion CNY | 632.63% |
| 2020 Q2 | 615.69 Million CNY | 782.14% |
| 2019 Q3 | 43.83 Million CNY | 0.51% |
| 2019 FY | 174.52 Million CNY | 25.43% |
| 2019 Q4 | 51.25 Million CNY | 16.93% |
| 2019 Q2 | 43.61 Million CNY | 21.81% |
| 2019 Q1 | 35.8 Million CNY | -9.37% |
| 2018 Q4 | 39.5 Million CNY | 0.0% |
| 2018 FY | 139.14 Million CNY | 28.95% |
| 2017 FY | 107.9 Million CNY | 23.13% |
| 2016 FY | 87.63 Million CNY | 0.0% |